4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion

/EIN News/ -- Press Release

4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion

• Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone payments of up to USD 740 million
• 4BIO Capital led the Series A in 2022, following its first investment in the Seed in 2020

London, United Kingdom, 17 March 2025 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Araris Biotech AG (“Araris” or “the Company”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs) has entered into an agreement to be acquired by Taiho Pharmaceutical Co., Ltd (“Taiho Pharmaceutical”). The acquisition follows a research collaboration between Taiho Pharmaceutical and Araris signed in November 2023 and is expected to be completed in the first half of 2025.

Under the terms of the agreement, Taiho Pharmaceutical will pay a USD 400 million upfront, with the potential for additional milestone payments of up to USD 740 million, and for a total amount of up to USD 1.14 billion.

Araris has been an investment out of 4BIO Capital Fund II, and the 4BIO team is proud to have actively supported the fast development and acquisition since the initial investment in 2020. In early 2020, 4BIO Capital recognised the significant potential of next-generation ADCs, however came to the conclusion that linker technologies needed to be improved to take the field to the next level. The 4BIO team subsequently identified Araris as the best-in-class linker-payload ADC platform to address the shortcomings of current generation ADCs. The Company’s AraLinQ™ technology enables the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, whilst ensuring long-term stability and safety of the resulting ADC, as well as increased antitumour effect compared to conventional ADCs. 4BIO Capital supported the company in the development of AraLinQ™ and its proprietary pipeline, leading its Series A in 2022 and supporting the company through multiple large pharma partnerships both as an investor and from the Board with Managing Partner Dima Kuzmin as Chairman, and Brian McVeigh and Dr Therese Liechtenstein as Board Observers.

Araris is advancing three products for the treatment of haematological and solid tumours developed using its unique AraLinQ™ technology, all of which are currently in the preclinical stage. These products are anticipated to enter into clinical trials between 2025 and 2026 and will benefit from Taiho Pharmaceutical’s clinical development expertise.

Dr Dmitry (Dima) Kuzmin, Managing Partner at 4BIO Capital and Chairman of Araris, commented, “The success of Araris is a perfect example of the 4BIO Capital playbook. We identified the technological hurdle that needed to be overcome to empower an up-and-coming drug class, identified the best science and the people to solve it and, alongside Araris’ management team, supported the company to secure multiple pharma partnerships, develop its own pipeline and now become part of the Taiho group. This acquisition confirms Araris’ position as one of the most exciting ADC companies in the market and has the potential to return over two times the fund to 4BIO Ventures II investors, further validating our science-driven, high conviction seed investment strategy.”

Dr Dragan Grabulovski, Chief Executive Officer and co-founder of Araris added, “We sincerely appreciate the support of Dima and the entire team at 4BIO in shaping our company, advancing our science, and helping us reach this important milestone. It’s the kind of investor that brings not only money to the table but also valuable strategic guidance, a network of industry connections, and a shared vision for transforming cancer treatment. Araris has developed a unique ADC technology that delivers different cancer-fighting drugs directly to tumours with high precision. This approach allows multiple treatment methods to work together at the same time while reducing harmful side effects. We are excited to join forces with Taiho Pharmaceutical whose deep expertise in oncology will be instrumental in accelerating the clinical development of our promising ADC candidates for both haematological and solid tumours.”

Philippe Fauchet OBE, Venture Partner at 4BIO Capital added, “We are delighted to see a seed investment we made in Europe find a skilled partner in a pioneering Japanese pharma company and are very happy to have facilitated the closer partnership. This deal further validates our strategy of building strong bridges between the Japanese and European biotech and pharma companies, which we believe will bring significant benefits to both ecosystems.”

Details of the acquisition can be found in the press release from Araris and Taiho Pharmaceutical here.

– End –

Contacts

4BIO Capital	+44 (0) 203 427 5500 info@4biocapital.com
ICR Healthcare Amber Fennell, Jonathan Edwards, Kris Lam	+44 (0)20 3709 5700 4biocapital@icrhealthcare.com

About 4BIO Capital

4BIO Capital (“4BIO”) is an international venture capital firm focused on investing in advanced therapies, including genomic medicines and other emerging technologies, to unlock the treatments of the future. 4BIO’s objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, connect with us on LinkedIn and Twitter @4biocapital and visit www.4biocapital.com.

About Araris Biotech AG

Araris Biotech is a leading independent company pioneering the future of antibody-drug conjugates (ADCs) and redefining the entire paradigm of targeted cancer therapy and beyond. Araris’ vision is a world without chemotherapy and its proprietary conjugation and groundbreaking multi-payload technology represents a quantum leap forward in ADC design, enabling the transformation of any antibody into an ADC with the goal of better safety and efficacy. By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a new generation of smart missiles that deliver the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent challenges of cancer resistance. Araris’ investors include 4BIO Capital, b2venture, Pureos Bioventures, Redalpine, Schroders Capital, VI Partners, Wille AG, Institute for Follicular Lymphoma Innovation and Samsung Ventures.

For more information about our science and pipeline, please visit https://www.ararisbiotech.com

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding lives. For more information about Taiho Pharmaceutical, please visit https://www.taiho.co.jp/en/